FDA: J&J Doribax pneumonia study halted on higher deaths
This article was originally published in Scrip
Executive Summary
A study of Johnson & Johnson's antibiotic Doribax (doripenem) was halted early after higher rates of death and poorer clinical cure rates were reported in patients receiving the drug, which was being tested in patients with ventilator-associated pneumonia, US regulators revealed on 5 January.